{
  "id": 19165070,
  "title": "Baird reiterates Faeth Therapeutics stock rating on clinical data",
  "url": "https://urgent.news/2026/11/09/baird-reiterates-faeth-therapeutics-stock-rating-on-clinical-data",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T14:44:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/baird-reiterates-faeth-therapeutics-stock-rating-on-clinical-data-93CH-5012573"
  },
  "original_language": "en",
  "account": "Baird maintained an Outperform rating and $57.00 price target for Faeth Therapeutics (FTH) on NASDAQ, following a clinical update. The target indicates significant upside potential from the current stock price of $12.21, aligning with the general analyst consensus ranging from $40 to $69. Over the past year, the stock has generated a 142% return, suggesting undervaluation based on Fair Value analysis. The company presented data from the Phase 2 PIK-201 study of PIKTOR combined with paclitaxel, highlighting competitive efficacy and a favorable safety profile. The trial demonstrated a low incidence of severe side effects, such as Grade 3 or higher stomatitis, and a minimal discontinuation rate. The objective response rate from the study presents an opportunity, given the positive progress-free survival results. This data supports the outlook for PIKTOR's potential in treating endometrial cancer, with Phase 3 trials already underway. Additionally, the evidence suggests PIKTOR's multi-nodal approach enhances efficacy without increasing toxicity. The firm anticipates positive results for the breast cancer opportunity, with further data expected in 2027.",
  "summary": null,
  "key_points": [
    "Baird maintains Outperform rating for Faeth Therapeutics (FTH) stock",
    "$57.00 price target indicates significant upside potential",
    "Phase 2 PIK-201 study shows competitive efficacy and safety profile"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}